Conversely, inhibition of ACLY diminishes the invasiveness of breast cancer cells, while targeting ACLY reduces the proliferative potential and cisplatin resistance of ovarian cancer cells (Lucenay et al., 2016; Wei et al., 2021). The gene discussed is ACLY; the disease is ovarian cancer.